The immunological basis of psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue SUPPL. 2, 2003, Pages 1-5

  Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti CD4+ monoclonal antibodies; Atopic dermatitis; CD45RO+ T cells; Cyclosporin; IL 2 fusion toxin; Psoriasis; T cell subsets; Th1 Th2 cytokines

Indexed keywords

ALEFACEPT; CD45 ANTIGEN; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 2; OKT 4; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11;

ARTICLE; ATOPIC DERMATITIS; CLINICAL OBSERVATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; IMMUNOBIOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; KIDNEY DISEASE; LABORATORY TEST; LYMPHOCYTE MIGRATION; MEMORY CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0038606337     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.17.s2.1.x     Document Type: Article

References (34)

1. Fry L. Psoriasis. Br J Dermatol 1988; 119:445-461.
2. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verret JL. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990; 126: 1523.
3. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990; 300: 908.
4. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-189.
5. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naive' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
6. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis. A disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 2002; 7:256-259.
7. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001; 126: 365-369.
8. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-1887.
9. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14: 63-78.
10. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998; 17: 269-278.
11. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
12. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990; 126: 351-355.
13. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
14. Rizova H, Nicolas JF, Morel P et al. The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 1994; 7: 1-13.
15. Kirby B, Griffiths CEM. Psoriasis: the future. Br J Dermatol 2001; 144 (Suppl. 58): 37-43.
16. Asumalahti K, Laitinen T, Itkonen-Vatjus R et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000; 9: 1533-1542.
17. Enerback C, Nilsson S, Enlund F et al. Stronger association with HLA-Cw6 than with corneodesmosin (S-gene) polymorphisms in Swedish psoriasis patients. Arch Dermatol Res 2000; 292: 525-530.
18. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110.
19. Cookson WO, Ubhi B, Lawrence R et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27: 372-373.
20. Lee YA, Wahn U, Kehrt R et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000; 26: 470-473.
21. Poizot-Martin I, Dhiver C, Mawas C, Olive D, Gastaut JA. Are CD4 antibodies and peptide T new treatments for psoriasis? Lancet 1991; 337: 1477.
22. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-321.
23. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.
24. Morel P, Revillard JP, Nicolas JF, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992; 5: 465-477.
25. Mueller W, Herrmann B, Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.
26. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-3116.
27. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
28. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
29. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
30. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252.
31. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-674.
32. Asadullah K, Docke WD, Ebeling M et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999; 135: 187-192.
33. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
34. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.